Influence of 5 antipsychotic drugs on liver function and heart function in the treatment of schizophrenia

doi:10.3969/j.issn.1673-8640.2018.03.002

Abstract

Abstract:

Objective To investigate the influence of 5 antipsychotic drugs （aripiprazole,clozapine,olanzapine,risperidone and quetiapine） on liver function and heart function in the treatment of schizophrenia. Methods A total of 192 schizophrenia patients were enrolled and randomly classified into 5 groups,including 38 cases in clozapine group,40 cases in olanzapine group,37 cases in risperidone group,35 cases in quetiapine group and 42 cases in aripiprazole group. Clozapine group received clozapine tablets orally,olanzapine group received olanzapine tablets orally,risperidone group received risperidone tablets orally,quetiapine group received quetiapine tablets orally,and aripiprazole group received aripiprazole tablets orally. The treatment course of each group was 8 weeks. The curative effect,Loewenstein Occupational Therapy Cognitive Assessment（LOTCA） score,Positive and Negative Syngrome Scale（PANSS） score,heart function,liver function and Treatment Emergent Symptom Scale（TESS） score before and after treatment were evaluated. Results The total effective rate showed no statistical significance （P>0.05）. LOTCA score was higher after treatment than that before treatment,and PANSS score was lower after treatment than that before treatment （P<0.05）. LOTCA score and PANSS score of each group after treatment had no statistical significance （P>0.05）. There were alanine aminotransferase（ALT） increasing,aspartate aminotransferase（AST） increasing and ALT+AST increasing without statistical significance （P>0.05）. Left ventricular ejection fraction and left ventricular end-diastolic diameter were lower after treatment than those before treatment （P<0.05）,and there was no statistical significance for left ventricular ejection fraction and left ventricular end-diastolic diameter of each group （P>0.05）. TESS scores of risperidone and quetiapine groups at 4 and 8 weeks were lower than those of clozapine,olanzapine and aripiprazole groups （P<0.05）. TESS scores of risperidone and quetiapine groups showed no statistical significance （P>0.05）. Conclusions Aripiprazole,clozapine,olanzapine,risperidone and quetiapine have curative effects for the treatment of schizophrenia,with a little influence on liver function and heart function,and can improve the cognitive ability of patients with psychiatric symptoms. Risperidone and quetiapine have mild adverse reactions.

Key words: Antipsychotic drug, Schizophrenia, Liver function, Heart function

CLC Number:

R446.1

KONG Lingguang, LIN Chongguang, HUANG Qianqian, LI Yanbin, XU Dali, XIE Hailong, ZHENG Cunqing, CHEN Xiaoying. Influence of 5 antipsychotic drugs on liver function and heart function in the treatment of schizophrenia[J]. Laboratory Medicine, 2018, 33(3): 196-200.

Figures/Tables 6

References 18

1	LIPSKA B K,LERMAN D N,KHAING Z Z,et al. Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs[J]. Eur J Neurosci,2015,18(2):391-402.
2	PIJNENBORG G H,TIMMERMAN M E,DERKS E M,et al. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: data from the European First-Episode Schizophrenia Trial (EUFEST)[J]. Eur Neuropsychopharmacol,2015,25(6):808-816.
3	STEFANOVI V,MIHAJLOVI G,NENADOVI M,et al. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia[J]. Vojnosanit Pregl,2015,72(12):1085-1092.
4	侯云跃,陈黎明,范林钰. 不同抗精神病药物对精神分裂症患者临床疗效和糖脂代谢的影响[J]. 西部医学,2015,27(6):843-846.
5	VANASSE A,BLAIS L,COURTEAU J,et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study[J]. Acta Psychiatr Scand,2016,134(5):374-384.
6	徐琼,梅双燕. 抗精神病药物联合心理干预对精神分裂症患者认知和社会功能的影响[J]. 实用临床医药杂志,2015,19(10):99-101.
7	沈渔邨. 精神病学[M]. 5版. 北京:人民卫生出版社,2009:841-845.
8	郑莜萸. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002:79-81.
9	SADOWSKA-BARTOSZ I,GALINIAK S,BARTOSZ G,et al. Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia[J]. Schizophr Res,2016,176(2-3):245-251.
10	MOLINS C,ROLDÁN A,CORRIPIO I,et al. Response to antipsychotic drugs in treatment-resistant schizophrenia: conclusions based on systematic review[J]. Schizophr Res,2016,178(1-3):64-67.
11	LOPEZ L V,KANE J M. Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia[J]. J Clin Psychiatry,2015,76(9):1249-1250.
12	赵路平. 氨磺必利与奥氮平治疗精神分裂症的对照研究[J]. 中国实用医药,2017,12(1):17-19.
13	贾维莹,毛叶萌. 阿立哌唑联合喹硫平治疗精神分裂症的疗效及安全性[J]. 实用临床医药杂志,2015,19(23):148-149.
14	郁婷婷. 利培酮与富马酸喹硫平治疗精神分裂症的临床疗效比较[J]. 临床合理用药杂志,2015,8(36):59-60.
15	张静,闽国庆. 奥氮平联合富马酸喹硫平治疗精神分裂症的临床观察[J]. 中国药房,2016,28(9):1173-1176.
16	张永梅,陈卫霞,柳烨,等. 氯氮平和氨磺必利治疗精神分裂症患者对肝功及血常规的影响[J]. 黑龙江医药科学,2015,38(3):138-139.
17	侯成业,陈智敏,温乃义,等. 3种非典型抗精神病药治疗精神分裂症对肝功能影响的对照研究[J]. 中国新药杂志,2015,24(8):908-911.
18	毕玉萍,罗小年. 常用抗精神病药物对肝功能影响的临床研究报道实录[J]. 中南药学,2013,11(2):150-153.

组别	例数	性别（男/女）	年龄（岁）	病程（月）
氯氮平组	38	25/13	34.17±5.38	7.32±1.50
奥氮平组	40	26/14	34.82±5.61	7.45±1.43
利培酮组	37	25/12	34.48±5.32	7.41±1.40
喹硫平组	35	22/13	34.60±5.67	7.45±1.45
阿立哌唑组	42	31/11	34.78±5.29	7.42±1.46
统计值		0.784	0.318	0.591
P值		>0.05	>0.05	>0.05

组别	例数	性别（男/女）	年龄（岁）	病程（月）
氯氮平组	38	25/13	34.17±5.38	7.32±1.50
奥氮平组	40	26/14	34.82±5.61	7.45±1.43
利培酮组	37	25/12	34.48±5.32	7.41±1.40
喹硫平组	35	22/13	34.60±5.67	7.45±1.45
阿立哌唑组	42	31/11	34.78±5.29	7.42±1.46
统计值		0.784	0.318	0.591
P值		>0.05	>0.05	>0.05

组别	例数	治愈	显效	有效	无效	总有效
氯氮平组	38	0（0.00）	25（65.79）	9（23.68）	4（10.53）	34（89.47）
奥氮平组	40	0（0.00）	24（60.00）	10（25.00）	6（15.00）	34（85.00）
利培酮组	37	0（0.00）	17（45.95）	13（35.13）	7（19.92）	30（81.08）
喹硫平组	35	0（0.00）	18（51.43）	9（25.71）	8（22.86）	27（77.14）
阿立哌唑组	42	0（0.00）	22（52.38）	12（28.57）	8（19.05）	34（80.95）

组别	例数	治愈	显效	有效	无效	总有效
氯氮平组	38	0（0.00）	25（65.79）	9（23.68）	4（10.53）	34（89.47）
奥氮平组	40	0（0.00）	24（60.00）	10（25.00）	6（15.00）	34（85.00）
利培酮组	37	0（0.00）	17（45.95）	13（35.13）	7（19.92）	30（81.08）
喹硫平组	35	0（0.00）	18（51.43）	9（25.71）	8（22.86）	27（77.14）
阿立哌唑组	42	0（0.00）	22（52.38）	12（28.57）	8（19.05）	34（80.95）

组别	例数	LOTCA评分		PANSS评分
组别	例数	治疗前	治疗后	治疗前	治疗后
氯氮平组	38	46.48±8.93	69.83±14.36^*	69.38±13.24	38.94±7.52^*
奥氮平组	40	45.39±9.13	65.42±13.87^*	67.84±12.35	40.13±8.19^*
利培酮组	37	46.25±9.46	67.13±12.91^*	68.64±11.97	37.97±6.98^*
喹硫平组	35	47.03±10.32	66.59±14.94^*	69.03±12.46	39.46±8.42^*
阿立哌唑组	42	45.38±8.71	67.54±11.65^*	68.79±10.42	38.96±7.46^*
F值		1.284	0.956	1.742	1.376
P值		>0.05	>0.05	>0.05	>0.05